Page last updated: 2024-08-26

fulvestrant and pf 573228

fulvestrant has been researched along with pf 573228 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnfather, P; Barrett-Lee, P; Bramble, P; Christensen, J; Hayes, E; Hiscox, S; Nicholson, RI	1

Other Studies

1 other study(ies) available for fulvestrant and pf 573228

Article	Year
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast cancer research and treatment, 2011, Volume: 125, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endocrine System; Enzyme Inhibitors; Estradiol; Focal Adhesion Protein-Tyrosine Kinases; Fulvestrant; Humans; Inhibitory Concentration 50; Phenotype; Quinolones; Sulfones; Tamoxifen	2011

Article

Year

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

Breast cancer research and treatment, 2011, Volume: 125, Issue:3

Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endocrine System; Enzyme Inhibitors; Estradiol; Focal Adhesion Protein-Tyrosine Kinases; Fulvestrant; Humans; Inhibitory Concentration 50; Phenotype; Quinolones; Sulfones; Tamoxifen

2011